Overview

Study of Combination PS-341 and Thalidomide in Multiple Myeloma

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
Phase:
Phase 1
Details
Lead Sponsor:
University of Arkansas
Treatments:
Bortezomib
Dexamethasone
Thalidomide